Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms
Mark Tristan J. Quimque, Kin Israel Notarte, Rey Arturo T. Fernandez, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 12, pp. 4316-4333
Open Access | Times Cited: 124

Showing 1-25 of 124 citing articles:

Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19
Nisha Muralidharan, Ramasamy Sakthivel, D. Velmurugan, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 7, pp. 2673-2678
Closed Access | Times Cited: 429
Discovery and development of safe-in-man broad-spectrum antiviral agents
Petter I. Andersen, Aleksandr Ianevski, Hilde Lysvand, et al.
International Journal of Infectious Diseases (2020) Vol. 93, pp. 268-276
Open Access | Times Cited: 224
Attenuation of Lipopolysaccharide-Induced Inflammatory Responses through Inhibition of the NF-κB Pathway and the Increased NRF2 Level by a Flavonol-Enriched n-Butanol Fraction from Uvaria alba
Kin Israel Notarte, Mark Tristan J. Quimque, Imee Macaranas, et al.
ACS Omega (2023) Vol. 8, Iss. 6, pp. 5377-5392
Open Access | Times Cited: 47
Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus
Akinwunmi Oluwaseun Adeoye, Babatunde Joseph Oso, Ige Olaoye, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 10, pp. 3469-3479
Open Access | Times Cited: 80
Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2
Kaifu Gao, Rui Wang, Jiahui Chen, et al.
Chemical Reviews (2022) Vol. 122, Iss. 13, pp. 11287-11368
Open Access | Times Cited: 58
Repurposing of Some Natural Product Isolates as SARS-COV-2 Main Protease Inhibitors via In Vitro Cell Free and Cell-Based Antiviral Assessments and Molecular Modeling Approaches
Hossam M. Abdallah, Ali M. El-Halawany, Alaa Sirwi, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 3, pp. 213-213
Open Access | Times Cited: 58
Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds With One Stone
Haihai Jiang, Peiyao Yang, Jin Zhang
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 43
Isolation of anticancer bioactive secondary metabolites from the sponge-derived endophytic fungi Penicillium sp. and in-silico computational docking approach
Kumaravel Kaliaperumal, Limbadri Salendra, Yonghong Liu, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 32
New progresses on cell surface protein HSPA5/BiP/GRP78 in cancers and COVID-19
Ting Li, Jiewen Fu, Jingliang Cheng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 26
Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review)
Silvia Vivarelli, Luca Falzone, Francesco Torino, et al.
International Journal of Oncology (2020) Vol. 58, Iss. 2, pp. 145-157
Open Access | Times Cited: 58
Targeting Host Defense System and Rescuing Compromised Mitochondria to Increase Tolerance against Pathogens by Melatonin May Impact Outcome of Deadly Virus Infection Pertinent to COVID-19
Dun‐Xian Tan, Rüdiger Hardeland
Molecules (2020) Vol. 25, Iss. 19, pp. 4410-4410
Open Access | Times Cited: 55
Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CLpro)
Shruti Koulgi, Vinod Jani, Mallikarjunachari Uppuladinne V N, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 15, pp. 5735-5755
Open Access | Times Cited: 53
Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
Pietro Delre, Fabiana Caporuscio, Michele Saviano, et al.
Frontiers in Chemistry (2020) Vol. 8
Open Access | Times Cited: 51
Alkaloids as Potential Phytochemicals against SARS-CoV-2: Approaches to the Associated Pivotal Mechanisms
Mohammad Bagher Majnooni, Sajad Fakhri, Gholamreza Bahrami, et al.
Evidence-based Complementary and Alternative Medicine (2021) Vol. 2021, pp. 1-21
Open Access | Times Cited: 47
Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations
Anastasiia I. Petushkova, Andrey A. Zamyatnin
Pharmaceuticals (2020) Vol. 13, Iss. 10, pp. 277-277
Open Access | Times Cited: 47
Computational search for potential COVID-19 drugs from FDA-approved drugs and small molecules of natural origin identifies several anti-virals and plant products
Abhishek Sharma, Vikas Tiwari, Ramanathan Sowdhamini
Journal of Biosciences (2020) Vol. 45, Iss. 1
Open Access | Times Cited: 44
An in-silico study on selected organosulfur compounds as potential drugs for SARS-CoV-2 infection via binding multiple drug targets
Liya Thurakkal, Satyam Singh, Rajarshi Roy, et al.
Chemical Physics Letters (2020) Vol. 763, pp. 138193-138193
Open Access | Times Cited: 39
Docking and in silico toxicity assessment of Arthrospira compounds as potential antiviral agents against SARS-CoV-2
Léna Petit, Léa Vernès, Jean‐Paul Cadoret
Journal of Applied Phycology (2021) Vol. 33, Iss. 3, pp. 1579-1602
Open Access | Times Cited: 39
Potential Cancer- and Alzheimer’s Disease-Targeting Phosphodiesterase Inhibitors from Uvaria alba: Insights from In Vitro and Consensus Virtual Screening
Mark Tristan J. Quimque, Kin Israel Notarte, arianne letada, et al.
ACS Omega (2021) Vol. 6, Iss. 12, pp. 8403-8417
Open Access | Times Cited: 35
Anti-HIV reverse transcriptase plant polyphenolic natural products with in silico inhibitory properties on seven non-structural proteins vital in SARS-CoV-2 pathogenesis
Von Novi O. de Leon, Joe Anthony Manzano, Delfin Yñigo H. Pilapil, et al.
Journal of Genetic Engineering and Biotechnology (2021) Vol. 19, Iss. 1, pp. 104-104
Open Access | Times Cited: 34
Natural Products for the Prevention and Control of the COVID-19 Pandemic: Sustainable Bioresources
Rajeev K. Singla, Xuefei He, Hitesh Chopra, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 34
Natural and Nature-Derived Products Targeting Human Coronaviruses
Konstantina Vougogiannopoulou, Angela Corona, Enzo Tramontano, et al.
Molecules (2021) Vol. 26, Iss. 2, pp. 448-448
Open Access | Times Cited: 33
Evaluation and characterization of HSPA5 (GRP78) expression profiles in normal individuals and cancer patients with COVID-19
Jiewen Fu, Chunli Wei, Jiayue He, et al.
International Journal of Biological Sciences (2021) Vol. 17, Iss. 3, pp. 897-910
Open Access | Times Cited: 33
Quinoline and Quinazoline Alkaloids against COVID-19: An In Silico Multitarget Approach
Esraa Ismail, Shaza W. Shantier, Mona S. Mohammed, et al.
Journal of Chemistry (2021) Vol. 2021, pp. 1-11
Open Access | Times Cited: 33
High-throughput virtual screening approach of natural compounds as target inhibitors of plasmepsin-II
Fatima En-Nahli, Soukayna Baammi, Halima Hajji, et al.
Journal of Biomolecular Structure and Dynamics (2022) Vol. 41, Iss. 19, pp. 10070-10080
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top